Forecast

The analysts' average price target is €32.06 (+107.64%). The median is €32.06 (+107.64%).

Buy	20
Hold	2
Sell	0

News Go to news feed

Syndax: recurring revenues from Revuforj and Niktimvo come into focus

At the H.C. Wainwright conference, Syndax presents a business model that already generates significant revenues but needs clinical data for further growth. Revuforj and Niktimvo each reach more than $200 million annually and drive growth, with Revuforj increasingly generating recurring revenue as a maintenance therapy after stem cell transplants. Near-term catalysts are expected data from axatilimab studies (IPF and frontline cGVHD) in the fourth quarter; the pipeline includes several oncology and rare-disease programs with clinical starts planned through 2027. Management expects expansion of the maintenance indication to be the dominant long-term revenue driver but sees a need for additional data to support that growth. » More on de.investing.com
Syndax: Revuforj establishes itself as market leader in a specific AML subgroup

Syndax reports that Revuforj is achieving an annualized revenue well over $200 million in its second year on the market and generated $55 million in the last quarter; market share is around 85% in relapsed/refractory AML with KMT2A and NPM1 mutations. Two approval-relevant phase III first-line studies (EVOLVE-2 for unfit patients, REVEAL for fit patients) are progressing well, while the company plans further label expansions and combination tests. In parallel, Syndax is advancing development of Niktimvo in IPF and cGvHD and new programs in lung cancer and myelofibrosis, with initial clinical starts for two projects planned for 2027. » More on de.investing.com
Syndax misses Q2 forecasts despite strong revenue growth, stock falls after hours

Syndax reported Q2 revenue of $73 million and a loss of $0.55 per share, missing both revenue and earnings expectations. Revenue grew 92% year‑over‑year, driven by Revuforj (net revenue $54.7 million) and Niktimvo (collaboration revenue $18.1 million), and management expects projected annual revenues for both products to be well over $200 million. The company ended the quarter with $575 million in cash, reiterated its operating cost guidance for 2026, and cited several clinical data catalysts for the second half of the year; the stock fell after hours following the missed metrics. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2024, SYNDAX PHARMACEU.DL-,0001 has already paid €0.90 in dividends. The last payout was in June 2024.

Financials

In the last quarter, SYNDAX PHARMACEU.DL-,0001 had revenue of €63.78m and net profit of -€43.25m

(EUR)	June 2026	YoY
Revenue	63.78m	98.04%
Gross profit	60.97m	95.91%
Net profit	-43.25m	29.04%
EBITDA	-32.15m	40.74%

Fundamentals

Metric	Value
Market capitalization	€1.4bn
Number of shares	88.61m
52-week high/low	€22.17 - €11.25
Dividends	No
Beta	0.37
P/E ratio	-7.21
PEG ratio	-0.15
P/B ratio	107.15
P/S ratio	6.39

Company profile

Syndax Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt Therapien für die Behandlung von Krebs. Seine führenden Produktkandidaten sind SNDX-5613, das sich in der klinischen Phase 1/2 befindet und auf die bindende Interaktion von Menin mit dem Mixed-Lineage-Leukemia-1-Protein zur Behandlung von MLL-rearranged (MLLr) und Nucleophosmin-1-mutierter akuter myeloischer Leukämie (NPM1c AML) abzielt; und SNDX-6352 oder Axatilimab, ein monoklonaler Antikörper, der den Rezeptor für den koloniestimulierenden Faktor 1 (CSF-1) blockiert, für die Behandlung von Patienten mit chronischer Transplantat-gegen-Wirt-Krankheit (cGVHD). Das Unternehmen entwickelt auch Entinostat. Es hat außerdem eine Forschungs- und Entwicklungskooperation mit dem National Cancer Institute, eine Vereinbarung über klinische Studien mit der Eastern Cooperative Oncology Group und eine Lizenzvereinbarung mit Kyowa Hakko Kirin Co, Ltd. abgeschlossen. Syndax Pharmaceuticals, Inc. wurde im Jahr 2005 gegründet und hat seinen Hauptsitz in Waltham, Massachusetts, Massachusetts.

Name	SYNDAX PHARMACEU.DL-,0001
CEO	Michael A. Metzger
Headquarters	New York City, ny USA
Website	syndax.com
Sector	Materials
Industry	Chemicals
IPO	02/03/2016
Employees	298